The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue from collaboration agreements | 24,931 | - |
| Total operating expenses | 117,008 | - |
| Non-operating income | 7,569 | - |
| Net loss | -32,166 | -52,342 |
| Stock-based compensation expense | 4,593 | 10,499 |
| Impairment of long-lived assets | 10,733 | - |
| Depreciation and amortization expense | 460 | 1,071 |
| Reduction in carrying amount of right-of-use asset | 1,688 | 3,317 |
| Net accretion of discounts on marketable securities | 515 | 1,364 |
| Other | 30 | 48 |
| Accounts receivable | 4,341 | -901 |
| Prepaid expenses and other current and long-term assets | 572 | -3,974 |
| Accounts payable | -885 | 889 |
| Accrued expenses and other current liabilities | -2,015 | -6,103 |
| Operating lease liability | -1,461 | -2,833 |
| Deferred revenue | -6,756 | -3,399 |
| Net cash used in operating activities | -31,207 | -45,342 |
| Proceeds from maturities of marketable securities | 51,180 | 115,551 |
| Purchases of marketable securities | 46,683 | 47,320 |
| Purchases of property and equipment, net | 411 | 185 |
| Net cash provided by (used in) investing activities | 4,086 | 68,046 |
| Proceeds from issuance of common stock-At The Market | 7,526 | 0 |
| Proceeds from issuance of common stock-Stock Purchase Agreement | 0 | 0 |
| Proceeds from exercise of stock options | 107 | 0 |
| Payments for repurchase of common stock for tax withholding | 24 | 155 |
| Other | 164 | 109 |
| Net cash provided by financing activities | 7,773 | -46 |
| Net change in cash, cash equivalents and restricted cash | -19,348 | 22,658 |
| Cash and cash equivalents at beginning of period | 58,942 | - |
| Cash and cash equivalents at end of period | 62,252 | - |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)